NR4A1 and breast carcinoma: In the 8th edition of the American Joint Commission on Cancer (AJCC), which will be in use beginning of January 2018, hormone receptor-positive/HER2-negative and lymph node-negative breast cancer patients with a low-risk recurrence score of multigene breast cancer prognostic panels, such as ODX, Mammaprint, EndoPredict, PAM 50, and Breast Cancer Index, have been placed into the same prognostic category as T1a-T1b N0 M0 tumors, regardless of T size.